Clinical trial
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer
NCT00005070 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005070 |
|---|---|
| Title | Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer |
| Official title | A Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Advanced Cervical Carcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | irofulven |
| Start date | Jan 1, 2000 |
| Primary completion | May 1, 2001 |
| Completion | May 1, 2001 |
| First posted | Aug 9, 2004 |
| Last update posted | Jun 19, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: